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ABSTRACT:
Studies were conducted to characterize the absorption, disposi-
tion, metabolism, and excretion of 1,2-dibromo-2,4-dicyanobutane
(BCB; methyldibromoglutaronitrile) following iv, oral, and topical
administration to male Fischer 344 rats. Following iv administration
of [14C]BCB (8 mg/kg, 120 mCi/kg), no parent compound was de-
tected in the blood; however, its debrominated metabolite, 2-meth-
yleneglutaronitrile (2-MGN; Cmax 7.3 mg/ml), was observed up to 1
hr. Within 72 hr, greater than 60% of the dose was excreted in the
urine and 4.1% in the feces, and 6.6% was exhaled as 14CO2.
Although less than 5% of the dose was retained in tissues, ;12%
was bound to the erythrocyte fraction of the blood. Following oral
administration of [14C]BCB (80 mg/kg, 100 mCi/kg), approximately
85% of the dose was absorbed, whereas 72% of the dosed radio-
activity was recovered in the urine and 9.7% in the feces, 7.5% was
exhaled as 14CO2, 3.5% bound to tissues, and 2.6% bound to blood.
Although parent compound could not be detected in the blood
following oral administration, 2-MGN was detected (Cmax 0.32 mg/
ml). Following topical application of [14C]BCB (25 mg/kg, 50 mCi/
kg), less than 12% of the dose was absorbed, with the major route
of excretion being the urine (6.6% of dose). Urinary metabolite
profiles were nearly identical for each route of administration, and
the primary urinary metabolite was a mercapturate conjugate of
2-MGN that was identified as N-acetyl-S-(2,4-dicyanobutane)-L-
cysteine. BCB was found to be extremely labile in whole blood,
plasma, and glutathione containing solutions, and in each case the
formation of 2-MGN could be reduced by the alkylation of free-
sulfhydryls with N-ethylmaleimide. These results suggest that BCB
is totally debrominated prior to systemic distribution, and tissue
exposure to intact BCB seems to be exceedingly low regardless of
route of administration.
1,2-Dibromo-2,4-dicyanobutane (BCB,1 CAS registry no. 35691-
65-7) has a wide range of industrial and commercial applications. Its
primary use has been as an antimicrobial agent to inhibit the growth
of slime-forming bacteria and fungi. The use of BCB in cosmetic
formulations suggests potential for widespread human exposure. In-
terestingly, in these formulations BCB has been shown to be a weak
skin sensitizing agent in man (Hausen, 1993; Tostiet al., 1995).
Although no data are available in the open literature regarding the
specific toxicities of BCB, its oral LD50 in rats has been estimated to
be 800 mg/kg. BCB is not mutagenic inSalmonella typhimurium, nor
does it induce unscheduled DNA synthesis in IMR-90 human embry-
onic fibroblasts (Anonymous, 1994). However, in anin vitro Chinese
hamster ovary cell assay, BCB produced significant frequencies of
chromosome aberrations (Anonymous, 1994). Although BCB has
been shown to be relatively nonmutagenic in severalin vitro assays,
it shares structural similarity to several halide-containing compounds,
which have been shown to be carcinogenic in animal models.
BCB is structurally similar to ethylene-1,2-dibromide and 1,2-
dibromopropane, two compounds that have been well characterized
from both a biotransformation and carcinogenic standpoint
(Guengerich, 1994; Laget al., 1994; Van Duurenet al., 1985; Zoete-
melk et al., 1986). In both instances, glutathione conjugation and
oxidation play important roles in the carcinogenic potential of these
compounds. Glutathione reacts directly with ethylene-1,2-dibromide
to form the highly reactive episulfonium ion (Guengerich, 1994). This
electrophilic species is responsible for both the mutagenicity and
DNA binding associated with this compound. On the other hand,
1,2-dibromopropane is weakly mutagenic and does not directly inter-
act with glutathione to form the episulfonium ion (Laget al., 1994).
Although the formation of this reactive metabolite has been proposed,
this pathway does not seem to be a predominate route of biotransfor-
mation for 1,2-dibromopropane (Zoetemelkt al., 1986). Instead, the
primary metabolic pathway of 1,2-dibromopropane is oxidation fol-
lowed by glutathione conjugation.
Ethylene-1,2-dibromide and 1,2-dibromopropane differ only by a
single methyl group, but their ability to participate in carcinogenic
events is vastly different because of subtle differences in bioactiva-
tion. Although metabolic activation in many cases dictates the carci-
nogenic potential of halide-containing alkanes, very little is known
about the metabolism and fate of BCB. Therefore, the primary objec-
tive of this study was to determine the absorption, distribution, bio-
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transformation, and excretion of BCB following iv, oral, and topical
exposure in the male Fischer 344 rat.
Materials and Methods
Chemicals. Radiolabeled [14C-1,3]BCB (9.42 mCi/mmol) was obtained
from Wizard Laboratories (West Sacramento, CA). [14C-1,3]2-MGN was
synthesized by reacting [14C]BCB (90mCi, 7.0 mg) with glutathione (34.7 mg)
in 1.5 ml of saline for 3 hr at 37 °C. Both compounds were greater than 99%
pure as determined by HPLC radiochemical analysis and GC-MS analysis.
Unlabeled BCB was obtained from Calgon Corporation (Pittsburgh, PA). Its
chemical purity was determined to be greater than 99% by GC-MS analysis.
Animals. Male Fischer 344 rats (175–250 g) with and without jugular vein
cannulation (JVC) were obtained from Hilltop Lab Animals, Inc. (Scottdale,
PA). The animals were acclimated for 5–7 days in a temperature-controlled (25
°C) 12-hr light/12-hr dark cycle facility. The animals were provided food
(Teklad 4% mouse-rat diet, Harlan Teklad, Madison, WI) and waterad libitum.
The doses selected for the following animal studies were based on 1/10 (oral)
and 1/100 (iv) the oral LD50 of BCB in rat (800 mg/kg). Furthermore, these
doses were chosen because they were not acutely toxic.
Intravenous Administration. [14C]BCB (8 mg/kg, 120mCi/kg), in emul-
phor/ethanol/saline, 3:4:12 (v/v/v) was administeredvia a jugular vein cannula
to male Fischer 344 rats (over 5 sec). The injection (2 ml/kg) was followed by
an equal volume of normal saline to flush the cannula. The animals were then
placed in Nalgene metabolism cages to allow collection of urine and feces
throughout the experiment. Blood samples (250ml) were collectedvia the
jugular cannula at selected points (0, 1, 3, 5, 7, 10, 12, 15, 20, 30, and 45 min,
as well as 1, 6, 12, 24, and 48 hr) and analyzed immediately by HPLC. The
withdrawn blood volume was replaced with an equal volume of saline.
2-MGN was also iv administered at an equal molar ratio to that of BCB.
[14C]2-MGN (3.3 mg/kg, 120mCi/kg) in emulphor/ethanol/saline, 3:4:12
(v/v/v), was administeredvia a jugular vein cannula to male Fischer 344 rats,
and the study was performed as described above for [14C]BCB.
Oral Administration. [14C]BCB (80 mg/kg, 100mCi/kg) in corn oil (5
ml/kg) was administered orally by gavage to male JVC Fischer 344 rats. The
animals were then placed in Nalgene metabolism cages to allow collection of
urine and feces. Blood samples were collected at selected points (0, 15, 30, and
45 min, as well as 1, 2, 3, 4, 6, 8, 12, 24, and 48 hr). At the end of the 72-hr
experiment, the animals were subjected to carbon dioxide euthanasia.
Topical Administration. The in vivopercutaneous absorption of [14C]BCB
following topical application was determined using the method of Winter and
Sipes (1993). Following adhesion of the percutaneous traps and a recovery
period of at least 16 hr, 100ml of [ 14C]BCB (25 mg/kg, 50mCi/kg) in
ethanol/propylene glycol, 3:7 (v/v) was applied to the shaved backs of the
animals. Following topical application, rats were placed into Nalgene metab-
olism cages for the collection of urine and feces. Blood samples were collected
at selected points (0, 15, 30, and 45 min, as well as 1, 3, 4, 6, 8, 12, 24, 48, and
72 hr). At the end of the 72-hr experiment, the animals were euthanized by
carbon dioxide inhalation. The skin at the treatment site was washed with 50
ml of ethanol, and aliquots of the wash were analyzed for total radioactivity.
Furthermore, the excised skin site was analyzed for radioactivity by tissue
oxidation. Radioactivity adsorbed to the activated charcoal was desorbed by
exhaustive extraction with ethyl acetate. The aluminum traps were washed in
acetone (33 100 ml) and analyzed for total radioactivity.
Dispositional Studies.For each route of administration, rats were housed in
glass metabolism cages, and exhaled radiolabel was collected for 72 hr.
[14C]BCB equivalents associated with exhaled organics were trapped with
2-methoxyethyl ether (Mallinckrodt Chemical, Paris, KY), and14CO2 was
trapped with CarboSorb (Packard, Meriden, CT)/ethylene glycol (Mallinckrodt
Chemical), 2:1 (v/v). Trapping solvents were changed and measured for total
radioactivity by scintillation counting at 0.5, 1, 2, 4, 6, 8, 10, 12, 24, 48, and
72 hr following administration of [14C]BCB. Urine (6, 12, 24, 48, and 72 hr)
and feces (24, 48, and 72 hr) were also collected throughout the experiments.
At the end of the 72-hr experiment, the animals were euthanized by carbon
dioxide inhalation. Blood was collected immediately from the posterior vena
cava into a heparinized syringe, and major tissues (liver, lungs, kidneys, heart,
brain, stomach, spleen, testes, adipose, small and large intestine, as well as
gastrointestinal contents) were excised, weighed, and stored at280°C until
analyzed (Winter and Sipes, 1993). Blood, feces, and tissue samples were
analyzed for total radioactivity by sample oxidation (Winteret al., 1992). Body
composition estimates of 11% for adipose tissue, 8% for blood, 50% for
muscle, and 16% for skin were used (Birnbaumet al., 1980; Matthews and
Anderson, 1975).
Stability and Reactivity of BCB. To define the stability of BCB in both
whole blood and plasma, [14C]BCB (28 mg, 0.4mCi) was incubated at room
temperature or 37°C with whole blood and plasma (150ml) for various times.
At the end of the incubation, samples were extracted and analyzed by HPLC
as described below. To determine the role of free sulfhydryl moieties,N-
ethylmaleimide (40 mM) was added to the incubation before BCB. Further-
more, BCB was incubated for 10 min in physiological phosphate buffer
containing 25 mM of glutathione with and withoutN-ethylmaleimide (40 mM).
To determine the ability of BCB and 2-MGN to covalently bind to blood
constituents, [14C]BCB (28 mg, 0.4mCi) or [14C]2-MGN (11.6mg, 0.4mCi)
was incubated with whole blood (300ml) up to 8 hr with and without
N-ethylmaleimide (80 mM). After incubation, the blood was extracted with
ethyl acetate until radioactivity associated with extract was at or below back-
ground.14C equivalents in the solvent extract were measured by liquid scin-
tillation counting, whereas the blood fraction was analyzed for total radioac-
tivity by sample oxidation.
Data Analysis.The blood concentration-time data following iv bolus dos-
ing were analyzed by both compartmental and noncompartmental methods.
Disposition parameter values best describing a linear multicompartmental
model, and assuming first-order kinetics for all processes, were determined by
nonlinear regression analysis as previously described (Saueret al., 1997).
HPLC Analysis of BCB and its Metabolites. Blood samples were mea-
sured directly for total radioactivity by scintillation counting (23 25 ml of
whole blood). BCB and its metabolites were extracted from 150ml of blood
with 300 ml of ethyl acetate. The samples were vortexed, centrifuged, and
organic extracts removed. The extraction procedure was repeated two more
times, the extracts were pooled, and 150ml of water was added. Analytes were
forced into the aqueous fraction by evaporation of ethyl acetatevi vacuum
centrifugation. The samples (100ml) were injected onto a 2503 4.6-mm
Whatman Partisil ODS-2 (10 micron) column (Whatman, Hillsboro, OR), and
metabolites were eluted with a mobile phase of water and acetonitrile both
co taining 0.1% acetic acid at a flow rate of 1 ml/min with a total run time of
80 min as previously described (Saueret al., 1997). For analysis of urinary
metabolites, urine samples were diluted 1:2 (v/v) with acetic acid to approx-
imately pH 4 and centrifuged to remove any precipitate. Prepared urine
samples (100ml) were analyzed by HPLC as described above. Urine samples
were also incubated withb-glucuronidase (2000 units/ml) or sulfatase (100
units/ml) for at least 24 hr and then analyzed by HPLC.
Metabolite Identification Using MS and MS/MS Analysis. For metabo-
lite isolation and identification, pooled urine samples from each route of
administration were diluted 1:2 (v/v) with 0.5% acetic acid. Samples were
analyzed on a Finnigan TSQ 7000 triple quadrupole mass spectrometer (Finni-
gan MAT, San Jose, CA) equipped with an atmospheric pressure source.
Samples were introduced into the mass spectrometer ion source after on-
column separation of analytes utilizing the same HPLC system described
above or by direct flow injection at 0.3 ml/min. Ions withm/z values corre-
sponding to putative metabolites were subjected to collision-induced dissoci-
ation with argon gas, and the subsequent product ion signal masses were
analyzed to produce a product ion mass spectrum.
Due to the volatile nature of the metabolites, blood samples were also
extracted with ethyl acetate, and extracted metabolites were separated using a
Fisons GC-8000 gas chromatograph coupled to a Fisons MD800 quadrupole
mass spectrometer (Fisons Instruments, Beverly, MA). The samples (1ml)
were injected onto a DB5-MS capillary column (0.25-mm film thickness,
0.25-mm diameter, 30 m; J & W Scientific, Folsom, CA). The oven temper-
ature was initially maintained at 50°C for 5 min, then increased 10°C/min for
the next 25 min to a final temperature of 300°C, and maintained at 300°C for
5 min. The injector, source, and interface temperatures were 250, 250, and
275°C, respectively. Mass spectra were scanned fromm/z50 to 650 in 1 sec.
Results
Intravenous Administration. No BCB was detected in the blood
following iv administration (including the 1-min time point); how-
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ever, 2-MGN was found in the blood. Although 2-MGN was found in
relatively high levels (Cmax 7.3 mg/ml), its concentration declined
rapidly and by 1 hr was below the limit of detection. Within 6 hr,
.40% of the dose of [14C]BCB had been excreted into the urine (fig.
1A). Recovery of total radioactivity (at 72 hr) in the urine, feces, and
tissues is shown in table 1. Only a small percentage of the dose
appeared in the feces (4.1%), whereas 6.6% of the dose was exhaled
as14CO2. Tissue oxidation indicated that only 4.9% of the dose was
retained in tissues 72 hr after treatment, but 12.5% of the dose was
bound to the erythrocyte fraction of the blood. No single tissue
contained a large amount of the radioactive dose, instead the dose
seemed to be evenly distributed throughout the body.
The withdrawal of blood for the evaluation of blood kinetics was
found to have a profound effect on the disposition of BCB in the
whole animal as compared with the disposition studies where no
blood was withdrawn. Serial bleeding increased urinary excretion,
whereas it concomitantly decreased the amount of14C equivalents
bound to erythrocytes. This effect is likely due to the constant dilution
of the blood with the replacement volume of saline following blood
sampling. However, saline replacement and enhanced urinary excre-
tion did not alter the relative distribution of metabolites observed in
the urine and apparently had no effect on the overall metabolism of
BCB in the whole animal.
Intravenous administration of [14C]2-MGN resulted in a concen-
tration-time profile that could adequately be described by a biexpo-
nential equation, consistent with a linear two-compartmental model
(fig. 2). The average (6SD) terminal half-life (t1⁄2), apparent volume
of distribution at steady-state (Vss), and systemic body clearance (CLs)
values were, respectively: 60.6 3.7 min, 0.686 0.23 liters/kg,
11.5 6 0.4 ml/kgz min. The mean residence time was 58.46 18.6
min. The excretion pattern was similar to that following iv adminis-
tration of BCB. The radioactivity associated with the urine was
86.96 7.3% of the dose and 2.46 0.1% with the feces, and 2.96
0.3% was bound to the blood at 48 hr.
Oral Administration. Following oral administration of [14C]BCB,
72% of the dose was excreted into the urine, and 9.7% was excreted
into the feces (table 1). Cumulative excretion of radioactivity in the
urine and feces is shown in fig. 1B. The recovery pattern was virtually
identical to that following iv administration, except for a lag in the
excretion of 14C equivalent into the urine and CO2 likely due to
absorption of BCB or its metabolites from the gastrointestinal tract.
The radioactivity associated with the exhaled CO2 was 7.5% of the
dose. Although tissues retained 3.5% of the dose 72 hr after treatment,
the dose was evenly distributed among tissues including the liver and
gastrointestinal tract. Approximately 2.6% of the dose was bound to
FIG. 2. Whole blood concentration of intact 2-methyleneglutaronitrile following
intravenous bolus administration of [14C]BCB (8 mg/kg, 120mCi/kg) and
[14C]2-MGN (3.3 mg/kg, 120mCi/kg) to male JVC Fischer 344 rats.
Data represent mean6 SD (N 5 3). Thelinesrepresent the nonlinear regression
fit of the data [C5 2.63e20.38t 1 3.15e20.01t for 1,2-dibromo-2,4-dicyanobutane
(dashed line); C 5 6.79e20.60t 1 3.66e20.02t for 2-methyleneglutaronitrile (solid
lin )].
FIG. 1. Cumulative recovery of total radioactivity in the urine and feces
following (A) intravenous (8 mg/kg, 120mCi/kg), (B) oral (80 mg/kg, 100mCi/
kg), and (C) topical (25 mg/kg, 50mCi/kg) administration of [14C]BCB in male
Fischer 344 rats.
Note the break in the vertical axis of graph C. Data expressed as mean percentage
of dose6 SD (N 5 3).
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the blood at the end of the experiments. No parent BCB could be
detected in the blood following oral exposure; however, a small
amount of 2-MGN was present in the blood following oral adminis-
tration (Cmax0.32mg/ml). Although it seems that at least 85% of dose
was absorbed following oral administration, it is unlikely that BCB is
absorbed intact.
Topical Administration. Recovery and elimination of total radio-
activity following topical exposure is shown in table 1. Approximately
83% of the radioactive dose was associated with the activated char-
coal, skin trap, and skin at the site of application. Cumulative excre-
tion of absorbed radioactivity is shown in fig. 1C. The excretion
pattern of absorbed14C equivalent was similar to that observed
following iv or oral administration; 4.9% of the dose was recovered in
urine, and 0.6% was recovered in feces. Little radioactivity was
associated with the exhaled CO2 (0.4%) and organic vapors (0%),
whereas approximately 0.5% of the dose was bound to the skin at the
site of application. Although blood contained only a small amount of
radioactivity 72 hr after treatment (0.4% of the dose), approximately
th same amount was retained by the tissues (0.5% of the dose). Thus,
it seems that less than 12% of the dose was absorbed following topical
application.
Stability and Binding of BCB in Blood. When incubated with
whole blood, BCB was rapidly converted to 2-MGN. In less than 1
min, no BCB could be detected in the incubation mixture. Plasma also
converted BCB to 2-MGN; however, the rate of conversion was
significantly slower than whole blood. Following 10 min of incuba-
tion, ;5% of the spiked BCB remained intact. Interestingly, the
formation of 2-MGN could be inhibited by conjugating free-sulfhy-
dryls with N-ethylmaleimide. Glutathione-containing buffers were
also found to readily catalyze the conversion of BCB to 2-MGN (data
not shown). When added to buffers containing glutathione, BCB was
readily converted to 2-MGN. Oxidized glutathione (glutathione disul-
fide) was also a product of this reaction. Similar to plasma and blood,
glutathione-mediated conversion could be reduced withN-ethylmale-
imide preincubation.
Following longer incubations of [14C]BCB or [14C]2-MGN in
FIG. 3. Representative spectra of major blood and urinary metabolites obtained from male Fischer 344 rats following administration of [14C]BCB.
(A) Representative GC-MS EI spectra of 2-methyleneglutaronitrile (RT 24 min). (B) Representative LC-MS/MS (2esi) product ion spectra of [M-H]
2 m/z 268,
N-acetyl-S-(2,4-dicyanobutane)-L cysteine (RT 23 min). (C) Representative LC-MS/MS (2esi) product ion spectra of [M-H]
2 m/z284,N-acetyl-S-(2,4-dicyanobutan-2-
ol)-L-cysteine (RT 19 min). (D) Representative LC-MS/MS (2esi) product ion spectra of [M1H]
2 m/z109, propanoic-1,3-dicyanide (RT 9 min).
TABLE 1
Recovery of [14C]1,2-dibromo-2,4-dicyanobutane in male Fischer 344 rats
Route
Percentage of Radioactive Dose Recovereda
Urine Feces Blood Tissues Exhaled14CO2 Exhaled [
14C]organic Trap and Skin Siteb Total Recovery
Intravenous (8 mg/kg) 63.6 4.2 4.16 2.1 12.56 0.2 4.96 0.2 6.66 1.1 0.36 0.2 — 92.06 2.1
Oral (80 mg/kg) 72.06 6.4 9.76 4.0 2.66 0.3 3.56 0.4 7.56 0.1 0.26 0.1 — 95.56 5.8
Topical (25 mg/kg) 4.96 4.3 0.66 0.3 0.46 0.4 0.56 0.4 0.46 0.3 0 83.46 10.2 90.26 5.5
a Mean % of dose6 SD, N 5 3; studies were conducted for 72 hr.
b Includes percutaneous skin trap, activated charcoal, and skin at site of BCB application. At the site of application, approximately 0.5% of the dose was bound to the skin.
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whole blood, progressive binding of14C equivalents to the erythrocyte
fraction was observed. Binding increased with time and by 8 hr was
70 6 13% and 816 5% for BCB and 2-MGN, respectively. Incuba-
tion with N-ethylmaleimide resulted in a significant decrease in the
amount of binding for both BCB (76 0.1% bound) and 2-MGN
(23 6 2% bound).
Determination of Blood Metabolites. Following iv and oral ad-
ministration of [14C]BCB, HPLC analysis of blood revealed one
major radioactive peak (RT 24 min). A second peak was also observed
at later times following iv administration (RT 19 min). Representative
GC-MS analysis of the isolated peaks is shown in fig. 3. The mass
spectrum of the primary metabolite had a molecular ion corresponding
at m/z106. Furthermore, the EI spectra of this metabolite was char-
acteristic of 2-MGN (fig. 4,panel II). The HPLC and GC retention
time and mass spectra of this putative metabolite in the samples were
compared with authentic standards to verify compound identity. The
secondary peak (RT 19 min) was not identified because of its low
concentration in blood.
Determination of Urinary Metabolites. Following reversed phase
HPLC analysis of urine from rats treated intravenously, orally, and
topically with [14C]BCB, several radioactive peaks were detected (fig.
5). Each route of administration showed similar metabolite profiles. A
quantitative accounting of the urinary metabolites following each
route is shown in table 2. Neitherb-glucuronidase nor sulfatase
incubation had an effect on the metabolic profiles of the urine. The
principle urinary metabolite (RT 23 min) was identified asN-acetyl-
S-(2,4-dicyanobutane)-L cysteine (fig. 4,panel III). Another signifi-
cant urinary metabolite (peak RT 19 min) was identified asN-acetyl-
S-(2,4-dicyanobutan-2-ol)-L cysteine (panel IV). The metabolite peak
RT 9 min was identified as propanoic-1,3-dicyanide (panel V). Al-
FIG. 4. Metabolic scheme proposed for 1,2-dibromo-2,4-dicyanobutane in the male Fischer 344 rat.
1,2-Dibromo-2,4-dicyanobutane (I), 2-methyleneglutaronitrile (II ), N-acetyl-S-(2,4-dicyanobutane)-L cysteine (III ), N-acetyl-S-(2,4-dicyanobutan-2-ol)-L cysteine (IV),
and propanoic-1,3-dicyanide (V). *, location of 14C label; GS, glutathione conjugate; S-Cys-N-Acetyl, mercapturate conjugate; GSH, glutathione; R-SH, free sulfhydryl;
GSSG, glutathione disulfide; RSSG, mixed disulfide.
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though no parent was detected in the urine, a minor amount (,0.1%
of the dose) of 2-MGN was observed (panel II).
Discussion
The work described here represents a comprehensive study of the
absorption, disposition, metabolism, and excretion of BCB in the male
Fischer 344 rat. Foremost among our observations was that no parent
compound could be detected in the blood at any time regardless of the
route of administration, including iv. The debrominated product of
BCB, 2-MGN, was observed following both iv and oral administra-
tion. Although a portion of the dose was absorbed percutaneously, at
no time was BCB or its metabolites detected in the blood. When
administered topically, BCB was absorbed significantly slower and to
a lesser degree than when given orally. This lack of detection in the
blood is likely because of the slow absorption of BCB in conjunction
with its rapid metabolism. Thus, regardless of the route of adminis-
tration, it seems that this compound undergoes substantial presystemic
clearance, and it is improbable that any BCB that is absorbed intact
escapes debromination to gain access to the systemic circulation.
Because following either oral or topical administration no BCB actu-
ally reaches the systemic circulation as intact compound, tissue ex-
posure to BCB is exceedingly small or even nonexistent. However,
tissue exposure to 2-MGN is substantially greater.
Immediately following iv BCB administration, 2-MGN was found
in relatively high levels, and its concentration-time profile could
adequately be described by a biexponential equation, consistent with
a linear two-compartmental model. Interestingly, when 2-MGN itself
was iv administered, its concentration-time profile was nearly identi-
cal to that observed following BCB administration. Thus, it seems that
BCB is immediately converted to 2-MGN after iv administration.
Following administration of 2-MGN, there was a relatively limited
distributive phase, which correlated with a steady state volume of
distribution (0.68 liters/kg) that is not especially large, suggesting that
only a limited amount of 2-MGN distributes to the tissues. As a
consequence of its low rate of clearance (11.5 ml/kgz min) and small
apparent volume of distribution, 2-MGN has a disposition half-life of
60.6 min.
As discussed above, the principle metabolite of BCB detected in the
blood was 2-MGN. The rapid formation of 2-MGN suggests that the
bromine moieties of BCB are extremely labile and readily eliminated.
Whole blood and, to a lesser extent, plasma possess the ability to
debrominate BCB. This rapid conversion by whole blood is likely
responsible for the inability of our assay to detect BCB following iv
administration. The debromination of BCB seems to be mediated by
a free-sulfhydryl-dependent biotransformation pathway. Incubation of
BCB in glutathione-containing solutions results in the formation of
2-MGN, as well as oxidized glutathione (glutathione disulfide). From
the in vitro incubation experiments, it seems that two glutathione
molecules are required for the total debromination of BCB. However,
these nucleophilic attacks do not result in the formation of a stable
glutathione conjugate intermediate. An analogous reaction has been
previously described by Liveseyet al. (1982). This sulfhydryl-depen-
dent mechanism involves the nucleophilic attack of glutathione on a
dihaloalkyl substrate resulting inS-(beta-haloalkyl)glutathione forma-
tion; subsequent attack of a second thiol on the sulfur atom of the
conjugate yields glutathione disulfide, halide ion, and an alkene
product. It seems that the rapid conversion of BCB to 2-MGN follows
this same mechanism. Interestingly, 2-MGN was not a major metab-
olite detected in the urine, and it seems that following formation the
majority of 2-MGN is further metabolized, and its metabolites are
then excreted into the urine.
No information is available in the literature on the biotransforma-
tion, toxicity, or carcinogenicity of 2-MGN. However, 2-MGN is
structurally similar to several previously investigated nitrile-contain-
ing compounds and seems to follow common metabolic pathways
(Fennell et al., 1991; Silver et al., 1982). Following formation,
2-MGN undergoes glutathione conjugation or oxidation, both of
which are directed at the unsaturated portion of the molecule. The
primary route of biotransformation for 2-MGN is glutathione conju-
gation, which results inN-acetyl-S-(2,4-dicyanobutane)-L cysteine as
FIG. 5. HPLC radiochromatograms of pooled urine samples (6-, 12-, and 24-hr
collection; 48 hr included for topical) from male Fischer 344 rats following (A)
intravenous (8 mg/kg, 120mCi/kg), (B) oral (80 mg/kg, 100mCi/kg), and (C)
topical (25 mg/kg, 50mCi/kg) administration of [14C]BCB.
The peaks are identified byletters that correspond to those shown on table 2.
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the principal urinary metabolite (38–46% of the radiolabel in the
urine). A secondary route of metabolism is oxidation, which appar-
ently results in the formation of an epoxide intermediate (2-methyl-
eneglutaronitrile oxide). This reactive intermediate can be conjugated
by glutathione or hydrated, resulting in the formation ofN-acetyl-S-
(2,4-dicyanobutan-2-ol)-L cysteine and 1,2-dihydroxy-2-methylglut-
aronitrile, respectively. Further oxidation of 1,2-dihydroxy-2-methyl-
glutaronitrile leads to the loss of a methyl group (carbon 1 of the
molecule) and the formation of propanoic-1,3-dicyanide (;9% of the
dose). Loss of carbon 1 results in the exhalation of radiolabel in the
form of 14CO2 (;8% of the dose). Interestingly, the cyano moieties of
BCB seem to avoid metabolism, and unlike other cyano-containing
compounds, BCB dose not liberate cyanide. This difference is prob-
ably due to structural considerations in the molecule (Silveret al.,
1982). A schematic representation for the proposed metabolic fate of
BCB consistent with the data reported here is shown in fig. 4.
Another important finding was the significant amount of radiolabel
covalently bound to the erythrocyte fraction of the blood. This bound
fraction accounted for the presence of14C equivalents 72 hr after BCB
administration and could not be displaced with various solvent ex-
tractions. Although BCB is rapidly converted to 2-MGN,in vitro
incubation of BCB with whole blood resulted in an increased amount
of covalent binding with time. Furthermore, incubation of 2-MGN
with whole blood also resulted in binding that increased with time.
The kinetic profiles for binding were similar for BCB and 2-MGN.
From these data, it seems that BCB itself is not responsible for
covalent binding, but instead 2-MGN seems to mediate the majority of
erythrocyte binding. Alkylation of free-sulfhydryls, which inhibits the
conversion of BCB to 2-MGN in the blood, resulted in a significant
decrease in the amount of binding for both BCB and 2-MGN. It is,
however, unclear in the case of 2-MGN whether free-sulfhydryls are
required for further biotransformation or as targets for binding. Thus,
it seems that the conversion of BCB to 2-MGN as well as the presence
of free-sulfhydryls in whole blood are required to achieve maximal
covalent binding. Furthermore, the amount ofin vivo erythrocyte
binding was dictated by the route of administration. When BCB was
administered orally, 2.6% of the dose was bound, whereas 12.5% was
bound following iv administration. The difference in binding is likely
due to the high first-pass hepatic metabolism (glutathione conjuga-
tion) of 2-MGN following oral administration. Thus, this metabolite is
conjugated and unable to react with macromolecular binding sites on
the erythrocyte.
A portion of the dose was also retained in the tissue (0.8–4.9%).
Interestingly, the binding was not tissue specific and was evenly
distributed among tissues. Such a distribution pattern is likely because
of one of the metabolites of BCB binding to vascular tissue through-
out the body or because of the presence of blood-bound14C equiva-
l nts present in tissues. Interestingly, the route of administration had
no effect on tissue binding of BCB, including binding to hepatic and
gastrointestinal tissues. BCB has been previously shown to be a weak
s nsitizing agent in humans (Hausen, 1993; Tostiet al., 1995). This
adverse effect may be related to the macromolecular binding of BCB
and the formation of immunoreactive adducts (haptens). However,
further investigation is required to determine if BCB binding to tissues
plays a significant role in its ability to cause systemic sensitization.
In summary, results of this study indicate that BCB is absorbed to
various degrees following oral and topical administration. Although
absorption through the skin is significantly slower than from the
gastrointestinal tract, in both cases it is unlikely that BCB is absorbed
intact. However, any BCB that reaches the systemic circulation intact
is converted to 2-MGN as a result of the extremely rapid debromina-
ti n of BCB catalyzed by free-sulfhydryls in the blood. Thus, tissue
exposure to BCB, regardless of the route of administration (including
iv), is expected to be exceedingly low. However, this is not the case
for its primary metabolite, 2-MGN, which is biotransformed and
eliminated at a significantly slower rate. Furthermore, the debromi-
nated metabolites of BCB seem to be responsible for the majority of
macromolecular binding observed in the blood. Thus, any toxicity or
carcinogenicity observed following BCB administration is likely me-
diated by 2-MGN or one of its primary metabolites (i.e. epoxide
intermediate). Future studies should, therefore, determine the early
tissue disposition of 2-MGN, as well as the organ(s) responsible for its
metabolism. Furthermore, because a significant portion of the dose
was found bound to tissues and the erythrocyte fraction of the blood,
the possible toxic ramifications of these observations should be in-
vestigated.
Acknowledgments.We acknowledge the Analytical Core of the
Southwest Environmental Health Science Center. Special thanks to
Dr. Thomas McClure and Mary Lou Eckerson for providing assis-
tance with this project. Furthermore, we thank Drs. H. B. Matthews
and M. L. Cunningham of the National Toxicology Program (National
Institute of Environmental Health Sciences) for their advice and
support with these studies.
References
Anonymous (1994) Methyldibromoglutaronitrile: Final report.Cosmetic Ingredient Review.
Washington, D.C.
Birnbaum LS, Decad GM and Matthews HB (1980) Disposition and excretion of 2,3,7,8-
tetrachlorodibenzofuran in the rat.Toxicol Appl Pharmacol55:342–352.
Fennell TR, Kedderis GL and Sumner SC (1991) Urinary metabolites of [1,2,3-13C]acrylonitrile
in rats and mice detected by13C nuclear magnetic resonance spectroscopy.Chem Res Toxicol
4:678–687.
Guengerich FP (1994) Mechanisms of formation of DNA adducts from ethylene dihalides, vinyl
halides, and arylamines.Drug Metab Rev26:47–66.
Hausen BM (1993) The sensitizing potency of Euxyl K 400 and its components 1,2-dibromo-
2,4-dicyanobutane and 2-phenoxyethanol.Contact Dermatitis28:149–153.
Lag M, Omichinski JG, Dybing E, Nelson SD and Soderlund EJ (1994) Mutagenic activity of
TABLE 2













Undefined 3 A 1.2 1.5 0.3
Propanoic-1,3-dicyanide 9 B 9.2 8.9 1.3
Undefined 16 C 2.4 2.1 0.3
N-Acetyl-S-(2,4-dicyanobutan-2-ol)-L cysteine 19 D 9.2 7.6 1.1
N-Acetyl-S-(2,4-dicyanobutane)-L cysteine 23 E 38.8 46.4 1.6
2-Methyleneglutaronitrile 24 — ,0.1% ,0.1% ,0.1%
Total dose in urine 60.8 66.5 4.6
Pooled urine samples from three rats per route of administration; oral and intravenous studies (0–24 hr), and topical (0–48 hr).
a HPLC retention time.
b See Fig. 5.
435ADME OF 1,2-DIBROMO-2,4-DICYANOBUTANE
halogenated propanes and propenes: Effect of bromine and chlorine positioning.Chem Biol
Interact 93:73–84.
Livesey JC, Anders MW, Langvardt PW, Putzig CL and Reitz RH (1982) Stereochemistry of the
glutathione-dependent biotransformation of vicinal-dihaloalkanes to alkenes.Drug Metab
Dispos10:201–204.
Matthews HB and Anderson MW (1975) The distribution and excretion of 2,4,5,29,59-
pentachlorobiphenyl in the rat.Drug Metab Dispos3:211–219.
Sauer JM, Smith RL, Bao JQ, Kattnig MJ, Kuester RK, McClure TD, Mayersohn M and Sipes
IG (1997) Oral and dermal absorption, disposition kinetics and the metabolic fate oftrans-
methyl styryl ketone in the male Fischer 344 rat.Drug Metab Dispos25:371–378.
Silver EH, Kuttab SH, Hasan T and Hassan M (1982) Structural considerations in the metabolism
of nitriles to cyanidein vivo. Drug Metab Dispos10:495–498.
Tosti A, Vincenzi C, Trevisi P and Guerra L (1995) Euxyl K 400: Incidence of sensitization,
patch test concentration and vehicle.Contact Dermatitis33:193–195.
Van Duuren BL, Seidman I, Melchionne S and Kline SA (1985) Carcinogenicity bioassays of
bromoacetaldehyde and bromoethanol: Potential metabolites of dibromoethane.Teratogenesis,
Carcinog Mutagen5:393–403.
Winter SM and Sipes IG (1993) The disposition of acrylic acid in the male Sprague-Dawley rat
following oral or topical administration.Food Chem Toxicol31:615–621.
Winter SM, Weber GL, Gooley PR, MacKenzie NE and Sipes IG (1992) Identification and
comparison of the urinary metabolites of [1,2,3-13C]-acrylic acid and [1,2,3-13C]-propionic
acid in the rat by homonuclear13C nuclear magnetic resonance spectroscopy.Drug Metab
Dispos20:665–672.
Zoetemelk CE, Oei IH, van Meeteren-Walchli B, Onkenhout W, van der Gen: A and Breimer DD
(1986) Biotransformation of 1,2-dibromopropane in rats into four mercapturic acid derivatives.
Drug Metab Dispos14:601–607.
436 SAUER ET AL.
